Skip to content
Screener

Supernus Pharmaceuticals SUPN Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$165.5MMiss by $2.8M
EPS$0.91Beat by $0.44
Revenue estimate$168.2M
EPS estimate$0.47

Next report

Nov 3, 2026 (in a month)
Revenue estimate$218.3M
EPS estimate$0.62

Financials

Q2 2025

Income statement

See full
Revenue$165.5M-1.7%
Gross profit$148.6M-1.2%
Operating income$12.1M-46.2%
Net income$22.5M+13.0%
EPS (diluted)$0.40+11.1%

Balance sheet

See full
Cash & equivalents$144.7M+178%
Total debt$31.8M-20.5%
Total equity$1.1B+11.1%
Total assets$1.4B+5.1%

Cash flow

See full
Operating cash flow$58.5M+64.3%
CapEx$455.0K+611%
Free cash flow$58.1M+63.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.77B+21.0%
Enterprise value$1.66B+14.2%
P/E27.5×-252×
P/S2.7×+0.3×

Profitability

See full
Gross margin88.5%+0.2pp
Operating margin9.6%+5.4pp
Net margin9.7%+8.9pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity6.4%+5.8pp
Debt / equity0×0.0×
Current ratio2.6×+0.7×

Segments

By product

See full
Qelbree$77.5M+30.6%
GOCOVRI$36.7M+15.6%
APOKYN$12.8M-25.9%
Oxtellar XR$11.6M-60.6%
Trokendi XR$11.2M-34.5%

By segment

See full
Reportable Segment$165.5M-1.7%

FAQ

When did Supernus Pharmaceuticals report Q2 2025 earnings?
Supernus Pharmaceuticals (SUPN) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Supernus Pharmaceuticals's Q2 2025 revenue and EPS?
Supernus Pharmaceuticals reported revenue of $165.5M and eps of $0.91 for Q2 2025.
Did Supernus Pharmaceuticals beat estimates in Q2 2025?
Revenue missed the consensus estimate of $168.2M by $2.8M. EPS beat the consensus estimate of $0.47 by $0.44.
How did Supernus Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.7% from $168.3M a year earlier and eps grew 152.8% from $0.36.
Where can I find Supernus Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001356576-25-000050) and the 10-Q periodic report (0001356576-25-000055) directly on SEC EDGAR. The filing index links above go to sec.gov.